AI May Help With MRI Interpretation During Prostate Cancer Detection

Commentary
Video

Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.

CancerNetwork® spoke with Wayne G. Brisbane, MD during Prostate Cancer Awareness Month 2023 about how implementing artificial intelligence (AI) into the clinical landscape may help in detecting prostate cancer more effectively in patients who need to undergo an MRI.

Brisbane, an assistant professor of urology at the University of California, Los Angeles (UCLA) Health, discussed his experiences with a machine learning algorithm called Unfold AI in patients with elevated prostate specific antigen (PSA) levels who need to proceed to an MRI, which his practice often employs in prostate cancer detection. He described how the AI program may be able to elucidate signs of disease in an MRI that are not typically perceptible to the human eye, thereby giving information on how best to manage the tumor.

Transcript:

AI is being used in prostate cancer in a couple of different ways, mostly on the diagnostic side. I use it in men who come in with an elevated PSA, which is our best and most reliable way to screen men for prostate cancer. If you have an elevated PSA—I tell men it’s like a thermometer for your prostate; it goes up for all kinds of reasons—maybe it’s something in the prostate that could just be size or some inflammation, but it could be prostate cancer. [Therefore], we need to figure out exactly what that is for men.

We’re using AI to interpret the MRIs. After a PSA elevation, oftentimes men will get an MRI or a biomarker [assessment]—in my [practice], we use MRI quite a bit. We will use the MRIs, and if it doesn’t look like there’s anything to the naked eye, we’ll have an AI go and take a second look at it. [From there] if there is a lesion on the MRI and we do a biopsy. We’re using a machine learning algorithm called Unfold AI that carefully predicts the location and extent of the tumor. We use that to help us perform treatments.

Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Related Content